Immunotherapy Diagnostics Expertise
Illuminate immunotherapy treatment opportunities with Caris Molecular Intelligence®. We provide oncologists reliable molecular information to inform immunotherapy treatment decisions using validated assays for PD-L1, MSI and TMB testing in our state-of-the-art laboratory.
- Programmed Death Ligand-1 (PD-L1) is among the most important immune checkpoint proteins that mediate tumor-induced suppression through T-cell downregulation. PD-L1 expression may indicate a more likely response to immunotherapies.
- Microsatellite Instability (MSI) is caused by failure of the DNA mismatch repair (MMR) system. MSI-High correlates to an increase neoantigen burden, which is more likely to respond favorably to immunotherapies.
- Tumor Mutational Burden (TMB) measures the total number of non-synonymous somatic mutations identified per megabase of the genome coding area. Tumors with high TMB likely harbor neoantigens and may respond more favorably to immunotherapies.
Our Comprehensive Genomic Profiling PLUS (CGP+) approach to assess DNA, RNA and Proteins reveals the highest quality molecular blueprint to guide more precise and individualized treatment decisions that are proven to extend overall survival.